WELL Health Technologies Delivers Strong 2024 Financial Results
Overview of WELL Health's 2024 Performance
WELL Health Technologies Corp. reported an impressive annual revenue of $919.7 million for 2024, marking a significant 19% increase compared to the previous year. Although the reported revenue was affected by the delay in recognizing revenue for Circle Medical, amounting to $56.6 million, and uncertainties surrounding $24.5 million from CRH due to the Change Healthcare cyberattack, the company remains on track to attain record revenue of $1.0 billion if excluding these impacts.
Financial Highlights
The company's Free Cash Flow Attributable to Shareholders (FCFA2S) also saw notable growth, reaching $49.3 million, representing a ~16% increase from $42.4 million in 2023. However, the Adjusted EBITDA for 2024 was $46.7 million compared to $113.4 million in 2023. Excluding the repercussions of the Circle Medical and CRH situations, WELL Health was positioned to achieve an Adjusted EBITDA of $127 million in 2024, reflecting an impressive 12% growth year-over-year.
Outlook for 2025
Looking ahead, WELL Health anticipates a robust 2025 with expected revenues between $1.40 and $1.45 billion and Adjusted EBITDA anticipated to fall within $190 million to $210 million. This forecast reflects full consolidation of HEALWELL's results per IFRS requirements and expects most deferred Circle Medical revenue to be recognized during 2025. However, the guidance does not factor in any contributions from CRH's delayed earnings until a resolution with Change Healthcare occurs.
Growth Strategy and Market Presence
Hamed Shahbazi, Chairman and CEO, emphasized the company's strong fundamentals despite the financial setbacks. In 2024, WELL Health facilitated 5.7 million patient visits, a staggering 32% increase from the prior year, primarily driven by organic growth. The Canadian operations were particularly strong, achieving an estimated $387.4 million in revenue, a growth of 30%. The company is keenly focused on reaching $800 million in revenue and $100 million in Adjusted EBITDA by 2026 purely from Canadian operations.
Impact of Circle Medical Investigation
In 2024, Circle Medical faced scrutiny from U.S. regulators over its billing practices, leading to an expense of approximately $2.8 million for estimated settlement costs. The company identified that a significant revenue deferral of $56.6 million was necessary due to the criteria not being met for revenue recognition under IFRS standards. Most of this deferred revenue is projected to be realized in 2025, contributing positively to future financial performance.
Cybersecurity Challenges at Change Healthcare
WELL Health's operations at CRH Anesthesia were severely impacted by a cybersecurity attack experienced by Change Healthcare early in 2024. This incident resulted in delayed billing and cash collections, adversely affecting revenue recognition. Well into 2024, CRH updated its revenue recognition assumptions, indicating that approximately $24.5 million of revenue would not be recognized until collections began post-attack.
Strategic Acquisitions and Developments
WELL Health made headlines in 2024 through several key acquisitions to bolster its market position. Notably, the company closed the acquisition of a majority interest in C-health, enhancing its diagnostic capabilities. The strategic alliance with HEALWELL aims to utilize AI-driven solutions to launch clinical trials efficiently across more clinics, thereby streamlining operations and harnessing technology for enhanced healthcare delivery.
WELL Health's Mission and Vision
WELL Health continues to prioritize its mission to tech-enable healthcare providers through innovative technologies and services. Their solutions empower over 38,000 healthcare providers in the U.S. and Canada while establishing a robust ecosystem of over 200 clinics that support diverse healthcare needs, including primary and specialized care. This expansion aids in fulfilling WELL's commitment to improving patient outcomes globally.
Frequently Asked Questions
What was WELL Health's annual revenue for 2024?
WELL Health reported an annual revenue of $919.7 million for 2024.
How much did WELL Health's Free Cash Flow Attributable to Shareholders increase?
The Free Cash Flow Attributable to Shareholders increased to $49.3 million, a rise of approximately 16% compared to the previous year.
What are the projected revenues for WELL Health in 2025?
WELL Health anticipates revenues ranging between $1.40 billion to $1.45 billion for 2025.
How did the cybersecurity incident affect WELL Health's revenue?
The cyberattack on Change Healthcare led to revenue delays and impacted cash collections for WELL Health, specifically affecting its CRH operations.
What is WELL Health's mission?
WELL's mission is to tech-enable healthcare providers to positively impact patient outcomes through innovative technologies and comprehensive support services.
About The Author
Contact Dominic Sanders privately here. Or send an email with ATTN: Dominic Sanders as the subject to contact@investorshangout.com.
About Investors Hangout
Investors Hangout is a leading online stock forum for financial discussion and learning, offering a wide range of free tools and resources. It draws in traders of all levels, who exchange market knowledge, investigate trading tactics, and keep an eye on industry developments in real time. Featuring financial articles, stock message boards, quotes, charts, company profiles, and live news updates. Through cooperative learning and a wealth of informational resources, it helps users from novices creating their first portfolios to experts honing their techniques. Join Investors Hangout today: https://investorshangout.com/
The content of this article is based on factual, publicly available information and does not represent legal, financial, or investment advice. Investors Hangout does not offer financial advice, and the author is not a licensed financial advisor. Consult a qualified advisor before making any financial or investment decisions based on this article. This article should not be considered advice to purchase, sell, or hold any securities or other investments. If any of the material provided here is inaccurate, please contact us for corrections.